Icalziss (Calcium Chloride Dihydrate)

When administered intravenously, calcium chloride dihydrate dissociates into calcium ions (Ca2+), raising the ionized calcium concentration in the blood. The increased calcium enhances myocardial contractility, stabilizes cardiac cell membranes, and facilitates neuromuscular transmission by acting on calcium‑dependent channels and enzymes, while also neutralizing citrate‑bound calcium from transfused blood products.

The prescribed dose of Icalziss is individualized by the treating clinician based on the patient’s serum calcium level, body weight, underlying condition, rate of calcium loss, and renal function. No fixed regimen is provided; the prescriber sets the infusion volume and rate according to clinical judgment and laboratory monitoring.

Safety data for calcium chloride dihydrate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with an obstetrician or qualified healthcare professional.

To order Icalziss, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Icalziss (calcium chloride) provides calcium in a highly soluble, rapidly bioavailable form, delivering a higher elemental calcium per millilitre than calcium gluconate. This makes it useful for urgent correction of severe hypocalcemia. However, the higher calcium load can increase the risk of hypercalcemia, so careful monitoring is essential compared with more dilute preparations.

Icalziss should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from moisture, direct sunlight, and extreme temperature fluctuations. Inspect the vial for particulate matter or discoloration before use, and discard any product that appears compromised.

Icalziss is administered intravenously by slow infusion, typically through a peripheral or central line. The exact infusion rate and volume are determined by the prescribing clinician, who will consider the patient’s calcium status and clinical condition. Infusion should be performed under cardiac and blood‑pressure monitoring to detect any acute reactions.

Serious adverse events include cardiac arrhythmias (especially ventricular tachycardia), severe hypercalcemia that can impair renal function, tissue necrosis if the solution extravasates, anaphylactic reactions, and seizures. Prompt recognition and immediate medical intervention are required if any of these events occur.

Icalziss should be avoided in patients with known hypersensitivity to calcium chloride, uncontrolled hypercalcemia, severe renal impairment without appropriate monitoring, and in situations where rapid calcium infusion could exacerbate existing cardiac arrhythmias. Contraindications must be confirmed by the treating physician before administration.